Altimmune (ALT) Liabilities and Shareholders Equity (2010 - 2026)

Altimmune (ALT) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $335.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $335.6 million, up 113.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 65.81% YoY), and the FY2025 annual result was $279.9 million, up 100.95% from the prior year.
• Liabilities and Shareholders Equity grew to $335.6 million in Q1 2026 per ALT's latest filing, from $279.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $335.6 million in Q1 2026 and troughed at $139.3 million in Q4 2024.
• A 5-year average of $201.5 million and a median of $190.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity sank 33.87% in 2024, then soared 113.42% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $206.9 million in 2022, then gained by 1.79% to $210.6 million in 2023, then tumbled by 33.87% to $139.3 million in 2024, then soared by 100.95% to $279.9 million in 2025, then advanced by 19.9% to $335.6 million in 2026.
• Business Quant data shows ALT's Liabilities and Shareholders Equity at $335.6 million in Q1 2026, $279.9 million in Q4 2025, and $218.4 million in Q3 2025.